Nasdaq · CIK 0001782303
BOLD Boundless Bio, Inc.
Insider trading from SEC Form 4. Last filing Jan 26, 2026.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
11
with a Form 4 at this company
Signals
Open-market buys and sells at Boundless Bio, Inc., scored.
No scored open-market trades yet. Grants, exercises and other rows are below.
Transactions
The last 16 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 23, 2026 | David A Hinkle See Remarks | AGrant or award Stock Option (right to buy)derivative | +140,000 | $0.00 | $0 | 140,000 | Jan 26, 2026 |
| Jan 23, 2026 | Zachary Hornby President & CEO | AGrant or award Stock Option (right to buy)derivative | +600,000 | $0.00 | $0 | 600,000 | Jan 26, 2026 |
| Jan 23, 2026 | Robert Doebele Chief Medical Officer | AGrant or award Stock Option (right to buy)derivative | +230,000 | $0.00 | $0 | 230,000 | Jan 26, 2026 |
| Jan 23, 2026 | Christian Hassig Chief Scientific Officer | AGrant or award Stock Option (right to buy)derivative | +230,000 | $0.00 | $0 | 230,000 | Jan 26, 2026 |
| Jan 23, 2026 | Jessica Oien See Remarks | AGrant or award Stock Option (right to buy)derivative | +220,000 | $0.00 | $0 | 220,000 | Jan 26, 2026 |
| Jun 23, 2025 | Nancy Whiting director | AGrant or award Stock Option (right to buy)derivative | +16,000 | $0.00 | $0 | 16,000 | Jun 23, 2025 |
| Jun 23, 2025 | Kristina Burow director, owner | AGrant or award Stock Option (right to buy)derivative | +16,000 | $0.00 | $0 | 16,000 | Jun 23, 2025 |
| Jun 23, 2025 | Jonathan E Lim director | AGrant or award Stock Option (right to buy)derivative | +24,000 | $0.00 | $0 | 24,000 | Jun 23, 2025 |
| Jun 23, 2025 | Jennifer Lew director | AGrant or award Stock Option (right to buy)derivative | +16,000 | $0.00 | $0 | 16,000 | Jun 23, 2025 |
| Jun 23, 2025 | James Christensen director | AGrant or award Stock Option (right to buy)derivative | +16,000 | $0.00 | $0 | 16,000 | Jun 23, 2025 |
| Jun 23, 2025 | Christine Brennan director | AGrant or award Stock Option (right to buy)derivative | +16,000 | $0.00 | $0 | 16,000 | Jun 23, 2025 |
| Feb 3, 2025 | Robert Doebele Chief Medical Officer | AGrant or award Stock Optionderivative | +180,000 | $0.00 | $0 | 180,000 | Feb 3, 2025 |
| Jan 22, 2025 | Jessica Oien See Remarks | AGrant or award Stock Optionderivative | +90,000 | $0.00 | $0 | 90,000 | Jan 23, 2025 |
| Jan 22, 2025 | Zachary Hornby President & CEO | AGrant or award Stock Optionderivative | +295,000 | $0.00 | $0 | 295,000 | Jan 23, 2025 |
| Jan 22, 2025 | Christian Hassig Chief Scientific Officer | AGrant or award Stock Optionderivative | +95,000 | $0.00 | $0 | 95,000 | Jan 23, 2025 |
| Jan 22, 2025 | David A Hinkle See Remarks | AGrant or award Stock Optionderivative | +65,000 | $0.00 | $0 | 65,000 | Jan 23, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Christine Brennandirector
- Kristina Burowdirector, owner
- James Christensendirector
- Robert DoebeleChief Medical Officer
- David A HinkleSee Remarks
- Christian HassigChief Scientific Officer
- Zachary HornbyPresident & CEO
- Jennifer Lewcfo, officer, director
- Jonathan E Limceo, chair, officer, director, owner
- Jessica OienSee Remarks
- Nancy Whitingdirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.